DK3728207T3 - Quinazolinoner som parp14-inhibitorer - Google Patents
Quinazolinoner som parp14-inhibitorer Download PDFInfo
- Publication number
- DK3728207T3 DK3728207T3 DK18833588.9T DK18833588T DK3728207T3 DK 3728207 T3 DK3728207 T3 DK 3728207T3 DK 18833588 T DK18833588 T DK 18833588T DK 3728207 T3 DK3728207 T3 DK 3728207T3
- Authority
- DK
- Denmark
- Prior art keywords
- quinazolinones
- parp14
- inhibitors
- parp14 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608747P | 2017-12-21 | 2017-12-21 | |
| US201862691025P | 2018-06-28 | 2018-06-28 | |
| PCT/US2018/066700 WO2019126443A1 (en) | 2017-12-21 | 2018-12-20 | Quinazolinones as parp14 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3728207T3 true DK3728207T3 (da) | 2023-03-13 |
Family
ID=65013795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18833588.9T DK3728207T3 (da) | 2017-12-21 | 2018-12-20 | Quinazolinoner som parp14-inhibitorer |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10562891B2 (da) |
| EP (2) | EP4212515A1 (da) |
| JP (2) | JP7381485B2 (da) |
| KR (1) | KR20200103760A (da) |
| CN (1) | CN111699176A (da) |
| AU (2) | AU2018392616B2 (da) |
| BR (1) | BR112020012197A2 (da) |
| CA (1) | CA3085353A1 (da) |
| DK (1) | DK3728207T3 (da) |
| ES (1) | ES2941818T3 (da) |
| FI (1) | FI3728207T3 (da) |
| HR (1) | HRP20230183T1 (da) |
| HU (1) | HUE061595T2 (da) |
| IL (1) | IL275331A (da) |
| LT (1) | LT3728207T (da) |
| MD (1) | MD3728207T2 (da) |
| MX (1) | MX2020006365A (da) |
| PL (1) | PL3728207T3 (da) |
| PT (1) | PT3728207T (da) |
| RS (1) | RS64183B1 (da) |
| SI (1) | SI3728207T1 (da) |
| TW (1) | TWI813611B (da) |
| WO (1) | WO2019126443A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006365A (es) | 2017-12-21 | 2020-10-12 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). |
| WO2020046753A1 (en) | 2018-08-27 | 2020-03-05 | Oregon Health & Science University | Parp inhibitors for treating cancer and asthma |
| WO2021198191A1 (en) * | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| CN111423373B (zh) * | 2020-05-19 | 2024-01-19 | 瑞阳制药股份有限公司 | 硫酸羟氯喹的制备方法 |
| WO2022165118A1 (en) * | 2021-01-29 | 2022-08-04 | Ribon Therapeutics, Inc. | Methods of treating inflammatory diseases |
| CN115260164B (zh) * | 2021-05-01 | 2024-03-26 | 杭州星鳌生物科技有限公司 | 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用 |
| TW202342463A (zh) * | 2022-02-09 | 2023-11-01 | 美商律幫治療股份有限公司 | Parp14抑制劑之固體形式 |
| CN114634496B (zh) * | 2022-02-27 | 2024-04-19 | 复旦大学 | 吲哚酮取代-1,3-噻唑烷酮类衍生物及其制备方法和应用 |
| US20240051946A1 (en) * | 2022-07-29 | 2024-02-15 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| WO2024026081A1 (en) * | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607506B1 (fr) | 1986-12-02 | 1989-01-06 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| GB0030708D0 (en) | 2000-12-15 | 2001-01-31 | Imperial College | Single channel proteomics concepts |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| WO2005019221A1 (en) | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
| AR052019A1 (es) | 2004-10-15 | 2007-02-28 | Bayer Pharmaceuticals Corp | COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS |
| GB0914767D0 (en) | 2009-08-24 | 2009-09-30 | Sterix Ltd | Compound |
| WO2011036576A1 (en) | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
| WO2013091773A1 (en) | 2011-12-22 | 2013-06-27 | Merck Patent Gmbh | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| CA2877826C (en) * | 2012-07-09 | 2016-08-16 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| ES2632988T3 (es) * | 2013-07-31 | 2017-09-18 | Merck Patent Gmbh | Derivados de oxoquinazolinil-butanamida |
| WO2015073818A1 (en) | 2013-11-14 | 2015-05-21 | The Brigham And Women's Hospital, Inc. | Parp9 and parp14 as key regulators of macrophage activation |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| FI3674302T3 (fi) | 2014-04-23 | 2023-04-27 | Incyte Holdings Corp | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONEJA JA PYRATSOLO[3,4-c]PYRIDIN-7(6H)-ONEJA BET-PROTEIINIEN INHIBIITTOREINA |
| WO2017042380A1 (en) | 2015-09-11 | 2017-03-16 | Universite De Lille 2 Droit Et Sante | Novel 5-amino-2-thioimidazole compounds and their use |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| GB201615282D0 (en) | 2016-09-08 | 2016-10-26 | Univ Bath | Tankyrase inhibitors |
| AU2018300982A1 (en) | 2017-07-12 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| IL307995A (en) | 2017-09-22 | 2023-12-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| MX2020006365A (es) | 2017-12-21 | 2020-10-12 | Ribon Therapeutics Inc | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). |
| US20200407700A1 (en) | 2018-02-26 | 2020-12-31 | President And Fellows Of Harvard College | Compositions of parp14 modulators and/or mutants and therapeutic use thereof |
| WO2020046753A1 (en) | 2018-08-27 | 2020-03-05 | Oregon Health & Science University | Parp inhibitors for treating cancer and asthma |
| US20220388985A1 (en) * | 2019-06-19 | 2022-12-08 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| WO2022165118A1 (en) | 2021-01-29 | 2022-08-04 | Ribon Therapeutics, Inc. | Methods of treating inflammatory diseases |
| TW202342463A (zh) * | 2022-02-09 | 2023-11-01 | 美商律幫治療股份有限公司 | Parp14抑制劑之固體形式 |
-
2018
- 2018-12-20 MX MX2020006365A patent/MX2020006365A/es unknown
- 2018-12-20 FI FIEP18833588.9T patent/FI3728207T3/fi active
- 2018-12-20 KR KR1020207021282A patent/KR20200103760A/ko not_active Application Discontinuation
- 2018-12-20 ES ES18833588T patent/ES2941818T3/es active Active
- 2018-12-20 US US16/227,132 patent/US10562891B2/en active Active
- 2018-12-20 CN CN201880088833.4A patent/CN111699176A/zh active Pending
- 2018-12-20 BR BR112020012197-5A patent/BR112020012197A2/pt unknown
- 2018-12-20 EP EP22212226.9A patent/EP4212515A1/en active Pending
- 2018-12-20 EP EP18833588.9A patent/EP3728207B1/en active Active
- 2018-12-20 HU HUE18833588A patent/HUE061595T2/hu unknown
- 2018-12-20 HR HRP20230183TT patent/HRP20230183T1/hr unknown
- 2018-12-20 LT LTEPPCT/US2018/066700T patent/LT3728207T/lt unknown
- 2018-12-20 PT PT188335889T patent/PT3728207T/pt unknown
- 2018-12-20 AU AU2018392616A patent/AU2018392616B2/en active Active
- 2018-12-20 JP JP2020554054A patent/JP7381485B2/ja active Active
- 2018-12-20 DK DK18833588.9T patent/DK3728207T3/da active
- 2018-12-20 CA CA3085353A patent/CA3085353A1/en active Pending
- 2018-12-20 RS RS20230284A patent/RS64183B1/sr unknown
- 2018-12-20 SI SI201830904T patent/SI3728207T1/sl unknown
- 2018-12-20 TW TW107146131A patent/TWI813611B/zh active
- 2018-12-20 MD MDE20201102T patent/MD3728207T2/ro unknown
- 2018-12-20 WO PCT/US2018/066700 patent/WO2019126443A1/en active Application Filing
- 2018-12-20 PL PL18833588.9T patent/PL3728207T3/pl unknown
-
2020
- 2020-01-06 US US16/734,840 patent/US11008308B2/en active Active
- 2020-06-14 IL IL275331A patent/IL275331A/en unknown
-
2021
- 2021-04-14 US US17/230,099 patent/US11958837B2/en active Active
-
2023
- 2023-09-19 AU AU2023233066A patent/AU2023233066A1/en active Pending
- 2023-11-02 JP JP2023188422A patent/JP2024023224A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
| DK3788040T3 (da) | Pyridazinoner som parp7-inhibitorer | |
| DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
| DK3728207T3 (da) | Quinazolinoner som parp14-inhibitorer | |
| DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
| DK3464271T3 (da) | Pyrazolderivater som plasma-kallikreininhibitorer | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| DK3697785T3 (da) | Imidazo-pyridine forbindelser som pad-inhibitorer | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
| DK3302448T3 (da) | Erstattede heterocyclylafledninger som cdk-inhibitore | |
| DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| DK3580220T3 (da) | Aminotriazolpyridiner som kinasehæmmere | |
| DK3271349T3 (da) | Benzimidazolederivater som bromodomain-inhibitorer | |
| DK3538528T3 (da) | Pyrrolamider som alpha v-integrinhæmmere | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| DK3458460T3 (da) | Imidazoler som histondemethylase-inhibitorer | |
| DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer |